BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Viropro Inc. (VPRO) to Unlock Value from its Biosimilars Portfolio; Creates a Biosimilars Technology Subsidiary in Canada


5/16/2012 10:00:22 AM

IRVINE, Calif.--(BUSINESS WIRE)--VIROPRO (VPRO.PK). Viropro, Inc. creates a technology subsidiary to focus on the burgeoning International market for biosimilar drug therapeutics. Over the past year, several of the large pharmas have tied up with Contract Research Organizations (CROs) and/or with Contract Manufacturing Organizations (CMOs) to enter the field of biosimilars. With the US FDA publishing guidelines for biosimilar approvals earlier this year, and guidelines already in existence in the European Union, this activity has taken a leap forward as companies jostle for position to capture parts of what is expected to be lucrative, multi-billion dollar annuities for years to come. According to a Frost & Sullivan report (PharmaTimes, U.K., May 11, 2012), the European biosimilars market is forecast to grow to $3.99 billion in 2017 from $172 million in 2010. That is equivalent to compound growth of 56.7% a year. The expiration of patents for blockbuster biologics is expected to drive the growth.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->